Innovent Biologics Inc. (IVBIY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. De-Chao Yu Ph.D. | Co-Founder, Chairman & CEO | 5.01M | -- | 1964 |
| Mr. Hao Xi Ede | Executive Director & Fund Managing Partner | 976.68k | -- | 1959 |
| Ms. Cong Ding J.D. | General Counsel | -- | -- | -- |
| Ms. Vivian Zhang | Chief People Officer, GM & Executive Director | -- | -- | 1987 |
| Mr. Min Liu | Chief Commercial Officer | -- | -- | 1973 |
| Mr. Blake Salisbury | Senior Vice President | -- | -- | -- |
| Dr. Hui Zhou Ph.D. | Senior Vice President | -- | -- | -- |
| Dr. Samuel Suhua Zhang M.B.A., Ph.D. | Global Chief Business Officer | -- | -- | 1968 |
| Dr. Raj Dhodda Ph.D. | Senior Vice President | -- | -- | -- |
| Dr. Lei Qian M.D., Ph.D. | Senior Vice President | -- | -- | -- |
Innovent Biologics Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5,659
Description
Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retevmo, a selective and potent RET kinase inhibitor. The company is also developing Fucaso, a fully human (BCMA)-directed CAR-T cell; Dupert, a novel KRAS G12C inhibitor; DOVBLERON, a novel next-generation ROS1 TKI in-licensed ; Jaypirca, a non-covalent (reversible) BTK inhibitor; SYCUME, a recombinant IGF-1R monoclonal antibody; IBI354, a recombinant anti-HER2 ADC; IBI389, a first-in-class CLDN18.2/CD3 bispecific T cell engager; IBI3009,a potential best-in-class DLL3-targeting ADC; IBI3001, a potentially bispecific ADC against B7-H3 and EGFR; IBI3020,potential dual payload ADC targeting CEACAM5; IBI356,a potential anti-OX40L monoclonal antibody; IBI355,a potential anti-CD40L monoclonal antibody; IBI3002, a first-in-class TSLP/IL-4a bispecific antibod; IBI3016,a siRNA drug candidate targeting AGT; collaborated with SanegeneBio;and IBI112, a novel long-acting anti-IL-23. In addition, it develops IBI110, a novel anti-LAG3 monoclonal antibody; IBI939, a novel anti-TIGIT monoclonal antibody; IBI310, an anti-CTLA4 monoclonal antibody; IBI323, a novel LAG3/PDL1 bispecific antibody; IBI-363, a potential PD-1/IL2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI128, a late-stage novel non-purine xanthine oxidase inhibitor; and IBI311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products and provides consultation and research and development services. The company was incorporated in 2011 and is based in Suzhou, China.
Corporate Governance
Upcoming Events
March 26, 2025 at 10:59 AM UTC
Innovent Biologics Inc. Earnings Date
Recent Events
Recent Events Information Not Available